Amgen prepped to compete in US filgastrim market post Sandoz's Zarxio launch
Neupogen to bring in substantial future sales despite the arrival of Sandoz's biosimilar Zarxio in September, says Amgen.
Neupogen to bring in substantial future sales despite the arrival of Sandoz's biosimilar Zarxio in September, says Amgen.
Genomics services company Cellecta is offering gene-editing tool CRISPR to researchers wanting to “knock out” human gene functions.
The WHO says early results from Merck & Co’s Phase III Ebola vaccine trial show it is “highly effective” against Ebola and a “turning-point” in R&D.